Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors
Léa Berland1, Simon Heeke2,3,4, Olivier Humbert5,6, Adam Macocco1, Elodie Long‐Mira1, Sandra Lassalle1, Virginie Lespinet‐Fabre1, Salomé Lalvée1, Olivier Bordone1, Charlotte Cohen7, Sylvie Leroy8, Véronique Hofman7,1, Paul Hofman1, Marius Ilié1
1Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, University Hospital Federation OncoAge, 2UFR Médicine, 3Institute of Research on Cancer and Ageing of Nice (IRCAN), University Hospital Federation OncoAge, CNRS, INSERM, 4Department of Nuclear Medicine, Antoine Lacassagne Comprehensive Cancer Center, Université Côte d'Azur, Nice, France
2Institute of Research on Cancer and Ageing of Nice (IRCAN), University Hospital Federation OncoAge, CNRS, INSERM,
3Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, University Hospital Federation OncoAge,
4UFR Médicine,
5Antoine Lacassagne Comprehensive Cancer Center, Université Côte d'Azur, Nice, France;
6Department of Nuclear Medicine
7Department of Thoracic Surgery, 6Department of Pulmonary Medicine and Oncology, 7Hospital-Related Biobank (BB-0033-00025), Pasteur Hospital, University Hospital Federation OncoAge, Université Côte d'Azur, Nice, France
8Department of Pulmonary Medicine and Oncology,
Tóm tắt
Từ khóa
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
Journal of Thoracic Disease
Tập 11 Số S1
S71-S80
Thông tin tác giả